Sabine Jeromin

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Rüdiger Hehlmann, Michael Lauseker, Susanne Saußele et al. · Leukemia · 2017 · 339 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact

Panagiotis Baliakas, Sabine Jeromin, Michalis Iskas et al. · Blood · 2019 · 237 citations · Full text

Life Sciences, Hematology, Oncology +16

SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients

Sabine Jeromin, Claudia Haferlach, Frank Dicker et al. · Leukemia · 2013 · 220 citations

Life Sciences, Genetics, Molecular Genetics +12

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

Susanne Schnittger, Christiane Eder, Sabine Jeromin et al. · Leukemia · 2012 · 211 citations

Life Sciences, Genetics, Molecular Genetics +11

The role of different genetic subtypes of CEBPA mutated AML

Annette Fasan, Claudia Haferlach, Tamara Alpermann et al. · Leukemia · 2013 · 188 citations

Life Sciences, Genetics, Molecular Genetics +11